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ABSTRACT 
 The five-year survival rate of high-grade brain cancer patients remain very low at 
5% despite many years of research. The lack of effective treatments for brain tumors are 
mostly contributed to the complicated structure of brain tissue that renders drug delivery a 
challenging task. Chapter 1 provides an overview on the current status of brain tumor 
treatments and the challenges associated with them. Many efforts have been put into the 
design of various type of drug delivery systems, including viral, liposomal, and polymeric 
materials. However, many limitations such as immunogenicity, instability, and cytotoxicity 
still exist. Recently, our group has published a formulation for PEGylated poly(β-amino 
ester) or PBAE-based nanoparticles that exhibited widespread gene delivery in brain 
tumors. Here, we would like to adapt the formulation and investigate its ability in 
compacting mRNA, as mRNA possesses several advantages over DNA, including 
cytosolic delivery and the lack of danger for insertional mutagenesis. 
 Several structural differences exist between mRNA and DNA, and therefore an 
optimization of particle formulation is necessary. Chapter 2 discusses the optimization 
process of formulating PEG-PBAE-based mRNA particles, which involves the addition of 
tripolyphosphate (TPP). I demonstrated that the addition of TPP at a mRNA to TPP mass 
ratio of 1:2 led to great improvements in the polydispersity index, surface charge, and 
stability of the nanoparticles. 
 With the optimized particle formulation, I conducted in vitro and ex vivo 
experiments to compare the transfection efficiency of the PEG-PBAE mRNA particles and 
the PEG-PBAE DNA particles. Two types of reporter genes were used: enhanced green 
fluorescent protein (EGFP) and luciferase (Fluc), and two types of cell lines were tested: 
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9L and GL261. The experiments generated consistent results, showing that the mRNA-
carrying particles had higher cell-uptake and transgene expression compared to the DNA-
carrying particles. Multiple particles tracking ex vivo experiments confirmed that both 
types of particles exhibited similar diffusion in brain tissue, which was expected due to 
their similarity in size and charge.      
 The PEG-PBAE TPP mRNA particles showed promising data in vitro that provide 
a strong foundation for future in vivo experiments, including distribution and transfection 
in brain tumors and survival studies with mRNA gene therapy. I expect the mRNA particles 
to demonstrate two main advantages: 1) higher cell uptake leads to higher efficacy and 2) 
higher transfection efficiency of mRNA particles allows for lower dosages to be 
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CHAPTER 1: INTRODUCTION 
 
1.1 Brain Tumors 
Brain tumors can be categorized into two main groups: primary and metastatic. 
Primary brain tumors are those that arise from the brain tissue or its immediate 
surroundings, and they can be further separated into glial or non-glial primary brain 
tumors, where each type can be either benign or malignant. Metastatic brain tumors, are 
tumors that originate from other sites of the body and migrate to the brain [1], and over 
10% of metastatic brain tumors arose from lung cancer. Brain metastases have a 10 times 
higher incidence rate than that of primary brain tumors, and metastatic brain tumors are 
all considered malignant [2]. For the purpose of this study, we will focus on malignant 
primary brain tumors only.   
Malignant primary brain and other CNS tumors have an annual incidence rate of 
72,500 people with a mortality rate of 4.37 per 100,000 population, equivalent to 
approximately 16,000 people [3]. The most prevalent type of malignant primary brain 
tumors are gliomas, accounting for 78% of the category [1]. Within gliomas, 
astrocytomas are the most common. Astrocytomas arise from astrocytes, which are star-
shaped glial cells from the supportive tissue of the brain. Glioblastoma multiforme 
(GBM), which is a grade IV astrocytoma, is the most common and invasive type of 
primary brain tumor. GBM accounts for 45% of malignant primary brain tumors with an 
incidence rate of 3.2 per 100,000 population and a median survival of only 15 months 
even with optimal treatments, bringing to light the need of new therapeutic options [4].  
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1.2 Current Treatments and Limitations 
The three main treatments for brain tumors are surgery, radiation, or chemotherapy. 
Other non-conventional treatment options such as Optune® tumor treating fields, 
GLIADEL® wafer, and Bevacizumab (Avastin®) are also now available. 
1.2.1 Surgery 
Most patients would undergo surgery to remove as much of tumor tissue as 
possible from the brain without damaging surrounding health tissue. Recent advances in 
neurosurgery and imaging technology such as functional MRI and diffusion tensor 
imaging have helped improve the precision of brain surgeries through surgical navigation 
systems [5]. However, for highly aggressive tumor cases such as glioblastoma, surgical 
procedure is often unable to completely remove the tumor cells, as some have infiltrated 
into surrounding tissue and tumor vascularization [6]. The remaining tumor cells often 
leads to recurrence or disease progression [5]. Therefore, the standard therapy for GBM 
follows a multidisciplinary approach, which combines maximal safe surgical resection 
with radiation and chemotherapy[6]. 
1.2.2 Radiation 
Radiation therapy uses x-rays, gamma rays, neutrons, or protons to kill cells and 
shrink tumors by damaging DNA. Three main types of radiation therapy include standard 
external bean radiotherapy, proton beam treatment and stereotactic radiosurgery. 
Currently, there are no concrete evidence suggesting the superiority of one delivery 
method over another. Most radiation therapies are able to target specifically to the tumor 
and thereby minimizing damage to surrounding tissues. However, a major limitation of 
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radiation therapy is its toxic side effect, including headaches, hair loss, scalp changes, 
seizures, and memory loss [1].   
1.2.3 Chemotherapy 
Chemotherapy can be delivered in three forms: chemotherapy wafers, intravenous 
chemotherapy, or oral chemotherapy. Temozolomide (TMZ) is the most often prescribed 
oral chemotherapy drug for high grade gliomas. It is a lipophilic alkylating agent with a 
small molecular weight, allowing it to efficiently diffuse across the blood brain barrier 
(BBB) [7]. A phase III trial  or GBM in 2005 demonstrated the combination of TMZ and 
radiation therapy improved the two-year survival rate from 11% with radiation therapy 
alone to 27%, changing the standard of care for GBM [5]. However, a major limitation of 
TMZ lies within the mechanism of action itself. An alkylating agent triggers apoptosis by 
alkylating DNA at the N-7 or O-6 positions of guanine residues [8, 9], which can actually 
be repaired by a protein, O6-alkylguanine-DNA alkyltransferase (AGT), encoded in 
humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. Therefore, 
the expression of AGT diminishes the efficacy TMZ [10]. In addition, another limitation 
of chemotherapy in general is its side effects such as lung scarring and immune system 
suppression along with the unpredictability of success rate. Only 20% of patients with the 
most malignant primary brain tumors show positive responses [1].  
1.2.4 GLIADEL® Wafer 
GLIADEL® wafer is another type of chemotherapy delivery system that uses 
biodegradable polymers to deliver carmustine (BCNU), another alkylating agent under 
the cancer drug group Nitrosoureas. The wafers are placed on the surface of resected 
tumor and is designed to release the drug for 2 to 3 weeks. Clinical trials have 
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demonstrated that GLIADEL® wafer increased the median survival of newly diagnosed 
malignant glioma by 2 months and significantly reduced the risk of mortality by 27% as 
compared with patients who received placebo [11]. However, the number of adverse 
events were high, which include hemiplegia, convulsions, and brain edema. Another 
limitation is associated with the excessive diffusion of drug, causing a rapidly decline in 
drug concentration after being released from the wafer [12]. Tyler B. and coworkers have 
been testing a new polymeric formulation and drug content—BCMU-TMZ—to improve 
its performance. It has been shown to exhibit higher local drug concentration and create a 
stable and hydrophobic microenvironment for the drug [13].  
1.2.5 Optune® Tumor Treating Fields (TT Fields) 
In 2011, Optune® was approved by the U.S Food and Drug Administration (FDA) 
as a monotherapy for recurrent GBM after standard medical therapy options have been 
exhausted. Clinical trials demonstrated equivalent survival as compared to standard 
chemotherapy but with significantly fewer side effects, improving patients’ quality-of-life 
and making Optune® an attractive therapeutic option. 
 In 2015, Optune® received FDA approval as a treatment along-side TMZ for 
adults with newly diagnosed supratentorial GBM following standard-of-care treatment. 
The device uses TTFields, which delivers low-intensity, intermediate-frequency 
alternating electrical fields to tumor cells, causing cell deaths. The combination of 
Optune®  and TMZ increased progression free survival by 3 months (7.1 months versus 4 
months) with TMZ alone and also exhibited superior overall survival of 20.5 months 
versus 15.6 months [5].  
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1.2.6 Bevacizumab (Avastin®) 
Bevacizumab is a humanized monoclonal antibody that targets vascular 
endothelial growth factor, which is a protein essential for angiogenesis, a hallmark of 
cancer. The usage Bevacizumab was demonstrated to reduce vascular permeability and 
edema, improve oxygenation, and halting tumor growth. However, it failed to show 
improvement in patient overall survival, while also posing life-threatening adverse events 
such as hemorrhage, blood clots, and bowel perforation [5].   
 
1.3 Barriers for Brain Delivery 
One major obstacle hindering the drug development for brain cancers is the 
complexity of brain tissues and its surrounding environment that imposes multiple 
barriers for drug delivery and efficacy. 
1.3.1 Blood Brain Barrier 
The blood brain barrier (BBB) is a diffusion barrier essential for maintaining 
brain homeostasis by blocking the entrance of substances from the blood to the brain. In 
the brain, the capillary endothelial cells lack fenestrations, limiting the diffusion of 
molecules. The endothelial cells are also linked to a continuous barrier comprised of 
pericytes, astrocytes, and basal membrane via interendothelial junctions, and thus 
limiting the penetration of water-soluble substances. Efflux transporters in brain capillary 
endothelial cells further hinders molecules from entering the brain.  
Molecules cross the BBB through two main pathways: paracellular or 
transcellular. Small molecules such as ions and solutes passively diffuse pass the BBB 
paracellularly down the concentration gradients. For transcellular pathway, molecules can 
 6 
rely on passive diffusion, receptor-mediated transport, and transcytosis. The permeability 
of BBB depends on the molecular weight, charge, lipid solubility, and surface activity of 
the molecule. Small lipophilic molecules like carbon dioxide cross the BBB through 
passive diffusion, while proteins pass through endogenous transporters. Receptor-
mediated transcytosis has been the main focused for drug delivery to the brain [14]. 
1.3.2 Brain Tissue Barrier 
The brain extracellular space (ECS) is a tortuous path separated by cell bodies 
with different sizes and shapes, and the width of the intercellular spaces averages 
between 38-64 nm, creating an upper-bound limit for the size of drug delivery systems. 
Brain ECS is filled with interstitial fluid that contains negatively charged extracellular 
matrix made of several types of molecules such as hyaluronic acid, heparan sulfate, and 
chondroitin sulfate proteoglycan. The brain ECM serves as another barrier for drug 
delivery by increasing interstitial viscosity, regulating width of ECS, and inducing 
repelling or attracting forces [15]. 
1.3.3 Drug Rapid Clearance  
A third type of barrier system in brain is the blood-cerebrospinal fluid (CSF) 
barrier. Cerebrospinal fluid is a clear fluid that fills the ventricular system of the central 
nervous system (CNS) and the cisternae and subarachnoid space surrounding the brain 
and spinal cord. CSF undergoes molecule exchange with blood plasma and nearby brain 
tissue, and it is absorbed into the venous system in the subarachnoid space [16]. In human 
brain, there is approximately 140 mL of CSF, which is entirely produced and excreted to 
blood every 4-5 hours, equivalent to 4-5 times per day. This phenomenon can cause a 
rapid clearance of drug when delivered to the brain. When drug is delivered via CSF, the 
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drug is rapidly transported out of the brain and into the blood, from which the drug re-
enters the brain across the BBB. Once inside the brain, the diffusion of drug between 
brain’s intercapillary space is also instantaneous, as the drug exhibit immediate 
equilibration through the entire brain extravascular volume as soon as the molecule 
passes the blood barrier, causing a rapid decline in drug concentration [17].  
1.3.4 Tumor Heterogeneity 
Two types of heterogeneity exist for brain tumors: spatial and genotypic. 
Spatially, some regions in a tumor are hypoxic and necrotic, while other regions are 
normoxic. Some regions are proliferative and vascularized, while the others are quiescent 
and infiltrative. The differences in spatial property inside the tumor necessitates different 
drug delivery systems to achieve optimal efficacy. Genetically, key oncogenes such as 
epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor 
alpha (PDGFRA) show mosaic amplification in tumor. This result in varying cell 
expression of different receptor tyrosine kinases within the same tumor in a mutually 





CHAPTER 2: mRNA Nanoparticle Formulation and Characterization 
 
2.1 Introduction 
The structural complexity of the brain tissue and its surrounding areas in addition to 
the invasiveness of certain brain tumors bring to light the need of an efficient drug 
delivery system that is able to penetrate the BBB and BTB, avoid rapid clearance, and 
diffuse throughout the brain tumor. Important characteristics of an effective delivery 
system include small size (<100nm in diameter), biodegradable, biocompatible, nontoxic, 
stable, and prolong circulation time. It should be able to work as a carrier system for 
small molecules of drugs, peptides, or nucleic acids [18]. Many efforts have been put into 
the design of nanoscale drug delivery systems, which can be divided into two main 
categories: viral vector and non-viral vectors.  
2.1.1 Viral Vectors  
The potential of using viruses as gene delivery vectors have been studied over the 
past 25 years and they were the first gene therapy delivery vehicles to be used in glioma 
clnical trials. Many viruses have demonstrated efficacy in treating brain tumors 
preclinically, including neurotropic retroviruses and adenoviruses, which can infect 
neurons and glial cells. Currently, a phase II/III clinical trial for retrovirus Toca 511 and 
Toca FC are undergoing after a success in phase I trial that demonstrated that the 
treatment were well tolerated and mediated tumor regression in patients with recurrent 
high-grade glioma. Toca 511 and Toca FC is a suicide gene therapy, in which the 
retrovirus vector Toca 511 delivers the suicide gene, cytosine deaminase, that converts 
the prodrug Toca FC 5-fluorocytosine to its active form—5-fluorouracil—and kill tumor 
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cells by inhibiting DNA and protein synthesis. Other clinical trials with adenovirus have 
also been conducted, but have only shown small improvements in overall survival when 
combined with standard of care. The main limitation of viral vectors is the lack of tumor 
penetration efficiency that results in low transfection rate [19].   
 Other types of viral treatments include oncolytic viruses, which have the ability 
to destroy malignant tumor cells via infection and intracellular replication. Preclinical 
studies on recombinant oncolytic measles virus (MV) and parvovirus H-1 have shown to 
be effective in treating localized medulloblastoma and recurrent glioblastoma, 
respectively. However, the efficacy of oncolytic viruses are often reduced by innate 
immune responses or inherent therapeutic resistance in cancer cells [18].  
2.1.2 Non-Viral Vectors  
Non-viral vectors include non-polymeric and polymeric delivery system, and both 
of which have been studied extensively for glioma gene therapy. Non-polymeric delivery 
system includes micelles, liposomes and gold nanoparticles (NP), and polymeric delivery 
system includes polymeric nanoparticles and dendrimers. A combination of micelles and 
polymers to create a core/shell structure have also been studied [19].  
Micelles and Liposomes 
The main difference between micelles and liposomes is that micelles consist of 
lipid monolayer while liposomes are lipid bilayers. Micelles are self-assembling colloidal 
particles with a hydrophobic core and a hydrophilic shell, rendering them suitable for 
transporting water-insoluble drugs. Some recent developments of micelle delivery system 
include small long-circulating three-helix micelles and polymeric micelles that have 
shown good efficacy in delivery drugs to brain tumors [18]. 
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Liposomal delivery systems are usually modified with antibodies to enhance 
tumor targeting effect. A recent study reported an immunoliposome SGT-53 decorated 
with antitransferrin receptor (TfR) single chain antibody fragment (scFv), which targets 
highly-expressed TfR on tumor cells. The immunoliposome carries DNA plasmid 
encoding for p53, which downregulates MGMT, the DNA repair protein responsible for 
temozolomide resistance [18]. SGT-53 is currently undergoing a phase II clinical trial for 
combination therapy with TMZ in treating recurrent glioblastoma [19].  
The limitations of liposomes, however, include short shelf- and half-life, transient 
gene expression, and increased cytotoxicity for cationic lipids [19].  
Gold Nanoparticles 
 Gold nanoparticles are widely researched in areas beyond drug delivery, including 
tumor imaging, radiotherapy, and photo-thermal therapy. They are known for their 
biocompatibility and ease of synthesis and functionalization [20], but a major 
disadvantage of gold nanoparticles is their non-biodegradable nature. A type of gold 
nanoparticle containing siRNAs called NU-0129 is in early phase 1 clinical trial for 
recurrent glioblastoma or gliosarcoma. The particle carries siRNAs that target Bcl-2-like 
protein 12, which is involved in tumor progression and apoptosis resistance [19].  
Polymeric Nanoparticles 
 The overall advantages of polymeric delivery systems include their high tailoring 
ability, biodegradability, ease of functionalization, and good drug release profile. 
Polymers commonly used in nanoparticles are poly(lactide) PLA, poly(lactic-co-glycolic 
acid) PLGA polymer, and poly(β-amino ester) [18].  
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 Due to polymers’ ease of functionalization, many studies reported enhanced 
targeting effect when the polymeric nanoparticles were decorated with different peptides 
or ligands. A study using PEGylated PLA-based nanoparticle were shown to have a more 
selective accumulation in gliomas when decorated with a CK peptide. Another study 
showed more efficient brain tumor targeting of glioma cells when using ligand of 
interleukin-13 receptor α2 (IL-13Rα2) on PLGA nanoparticles [18]. 
Dendrimers 
Dendrimers are highly branched 3D polymers, and they have been used to deliver 
a variety of nucleic acids in glioma cells, including antisense oligonucleotides, 
microRNAs, siRNAs, and genes. A commonly studied dendrimer is the cationic 
poly(amidoamine) (PAMAM), which have shown to be able to penetrate the BBB. 
Similar to other polymeric NPs, dendrimers have been functionalized with peptides to 
enhance gene transfection. A limitation of dendrimers is its high cytotoxicity from 
cationic dendrimers, which can be mitigated by the commonly used PEGylation [19]. 
2.1.3 Biodegradable PBAE Particles  
Poly(β-amino ester), abbreviated as PBAE, has several advantages over other 
polymer systems: 1) it is biodegradable through a hydrolytic cleavage of ester groups 2) it 
is cationic which facilitates DNA compaction into nanoparticles 3) it has a high plasmid 
compaction volume 4) it has one of the best transgene expression among nonviral gene 
delivery systems 5) the polymer ends can be capped with different functional groups and 
generate a polymer library from which the best capping group can be selected to 
specifically target brain tumor cells [21]. 
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Many studies have used PBAE as a gene delivery method in glioma tissue in 
combination with convection-enhanced delivery (CED). One group studied the efficacy 
of suicide gene therapy with herpes simplex virus type I thymidine kinase (HSVtk) 
delivered by PBAE NPs in combination with ganciclovir, which showed improvements in 
survival [22].  Previous studies from our group have also shown widespread gene 
delivery in brain tumors as well as improvement in survival using PEGylated (PEG) 
PBAE nanoparticles carrying wild type p53 DNA plasmids [23]. A library of end capping 
groups was also tested for differences in distribution and transfection in the brain, which 
indicated that the C8 end-capping group (1,11-diamino-3,6,9-trioxaundecane) was most 
effective in gene delivery to brain tissues. However, these nanoparticles were only 
optimized and tested for DNA plasmids delivery, while mRNA compaction has yet to be 
evaluated. Therefore, this study focuses on optimizing the established PEG-PBAE NP 
formulation for mRNA delivery specifically, with the aim of designing a polymeric 
delivery system that provides better transfection efficiency compared to the DNA-
carrying PEG-PBAE nanoparticles.      
2.1.4 PBAE Nanoparticles with Tripolyphosphate 
Anionic tripolyphoshate is commonly used for chitosan-based nanoparticles, as 
the anionic charges are able to cross-link with chitosan to carry drugs and genes [24]. 
Huang et al. reported a study using tripolyphosphate to cross link with polyethylenimine 
(PEI) to form particles for siRNA delivery, which showed enhanced transfection and 
reduced cytotoxicity compared to pure PEI particles due to the masking of high cationic 
charge of PEI by the anionic TPP [25].  
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For our studies, the same protocol for PEG-PBAE DNA NP formulation was 
followed for the synthesis of PEG-PBAE mRNA NP except for the addition of TPP. We 
optimized our nanoparticle formulation using TPP, and examined the ability of TPP to 
compensate any inconsistencies in nanoparticle size and charge caused by structural 
differences between mRNA and DNA. 
 
2.2 Materials and Methods 
2.2.1 Polymer Synthesis 
The monomers for PBAE backbone polymer, which consists of 1,4-butanediol 
diacrylate and 4-amino-1-butanol, were purchased from Alfa Aesar (Ward Hill, MA). 
The chosen C8 end-capping group (1,11-diamino-3,6,9-trioxaundecane) were purchased 
from Tokyo Chemical Industry (Cambridge, MA). For the PEGylation reaction, 
methoxy-PEG- succinimidyl succinate were purchased from JenKem Technology (Plano, 
TX). Several solvents were used for the reaction, which were purchased as 
follows: ethyl ether anhydrous from Fischer Scientific (Pittsburgh, PA); dimethyl 
sulfoxide anhydrous (DMSO) and tetrahydrofuran (THF) from Sigma-Aldrich. 
The PBAE polymers were synthesized by a two-step Michael addition reaction, 
following the same procedure as previous reported [26]. First, 1,4-butanediol diacrylate 
and 4-amino-1-butanol were reacted at a 1.1:1 molar ratio at 90 °C for 24 hours to 
synthesize high–molecular-weight (MW) uncapped PBAE polymer (6.0–6.5 kDa). 
Polymers were then precipitated in cold ether three times to remove any unreacted 
species, dried under vacuum, and lyophilized. The molecular mass was determined using 
NMR, estimated to be 6.0–6.5 kDa, assuming two end acrylate groups per polymer and 
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characterized by gel permeation chromatography (GPC) (see Mastorakos et al. 
10.1073/pnas.1502281112, PNAS supplementary materials for NMR and GPC details) 
(24). The capping of end acrylate groups was done by dissolving PBAE backbone 
polymer in THF at 100 mg/mL and 30 molar equivalents of C8 capping groups to ensure 
end capping rather than further propagation. The reactions occurred while stirring at 
room temperature for 4–5 hours. The end-capped PBAE polymers were retrieved by 
precipitation in cold ether to remove unreacted groups, dried under vacuum, and 
lyophilized. Purity and complete end capping were confirmed by the absence of the 
acrylate proton peaks in the NMR spectrum (data not shown) [26]. 
The synthesis of PEGylated PBAE polymer (PEG-PBAE) involves a three-step 
reaction scheme. First, a PBAE polymer possessing lower MW was synthesized by 
reacting 1,4- butanediol diacrylates and 4-amino-1-butanol at a 1.2:1 molar ratio. Based 
on NMR analysis, the molecular mass was estimated to be 3.8–4.2 kDa, assuming two 
end acrylate groups per polymer. The low-MW PBAE polymer was then capped with C8 
as described earlier, and the end capping was confirmed by NMR. Subsequently, 
methoxy-PEG succinimidyl succinates were reacted with the two terminal primary amine 
groups at both ends of the C8-capped PBAE polymer chain. To do this, we transferred 
the resulting PBAE-C8 polymer and 2.05 molar equivalents of 5 kDa methoxy-PEG-
succinimidyl succinate to a glass vial, vacuumed, and purged with nitrogen. The mixture 
of reactants was dissolved in THF and reacted while stirring at room temperature 
overnight. The final PEG-PBAE polymer product was precipitated and washed with cold 
ether three times, dried under vacuum, and lyophilized. PEG conjugation was confirmed 
with NMR. Of note, the lower-MW PBAE polymer was used for the synthesis of PEG- 
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PBAE (at a PEG-to-PBAE molar ratio of 2:1) to increase the PEG-to-PBAE weight-to-
weight (wt/wt) ratio of the individual PEG-PBAE polymers and, thus, achieve a higher 
PEG content when particles are formulated at a fixed amount of PBAE polymer. All 
polymers were dissolved in DMSO at 100 mg/mL and stored at −20 °C for further use.  
2.2.2 Particle Formulation 
The luciferase-expressing DNA plasmids driven by the short-acting 
cytomegalovirus (CMV) promoter (i.e. pd1GL3-RL) was a kind gift from Professor 
Alexander M. Klibanov (M.I.T). The luciferase-expressing mRNA with stabilizing 
modified-nucleosides was a kind gift from Professor Drew Weissman (UPenn). The 
green-fluorescent protein (GFP)-expressing DNA plasmids driven by the CMV promoter 
were purchased from Clontech Laboratories Inc. (Mountainview, CA). The EGFP-
expressing mRNA with a stabilizing CleanCap® technology was purchased from 
TriLink® Biotechnologies (San Diego, CA). The DNA Plasmids were propagated and 
purified, as previously described [27, 28]. Briefly, plasmids were transformed into E. coli 
DH5α competent bacterial cells using a heat shock method, and following the bacterial 
expansion in LB media, plasmids were purified using EndoFree Plasmid Giga Kit 
(QIAGEN, Valencia, CA), as per manufacturer's protocol. 
The PEGylated PBAE C8 capped nanoparticles were formulated following 
protocols that were recently established from our group [23]. Briefly, 5 volumes of 
plasmid DNA or mRNA (0.1 mg/ml) were added drop-wise to 1 volume of polymer 
solution, consisting of a mixture of PBAE and PEG-PBAE at a w/w ratio of 2:3 based on 
PBAE mass and at a PBAE to plasmid DNA or mRNA ratio of 60:1 w/w. Using a 0.1 M 
hydrochloric acid solution, both the DNA or mRNA and the polymer solutions were 
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adjusted to pH 6.0. For mRNA particles that are formulated with TPP, appropriate 
volume of 0.5 mg/mL of sodium tripolyphosphate from Sigma-Aldrich was added to the 
mRNA solution to make a 2 TPP:1 mRNA ratio by mass. To maintain the same 
concentration of mRNA solution (0.1 mg/mL) as the established protocol, the volume of 
TPP added was subtracted from the original volume of ultrapure water necessary to dilute 
the mRNA concentration. Following formulation, nanoparticles were washed with 3 
volumes of ultrapure water, and concentrated to 1 mg/ml of plasmid DNA or mRNA 
using Amicon® Ultra Centrifugal Filters (100,000 MWCO, Millipore Corp., Billerica, 
MA). The concentration of the particles was estimated by calculating an average loss of 
DNA or mRNA after washing by using RF-5301PC spectrofluorophotometer (Shimadzu, 
Japan) to measure the concentration of 100% Cy®5 dye-labeled DNA or mRNA PBAE 
nanoparticle. The excitation and emission wavelengths used were at 649 and 670, 
espectively. A standard curve with Cy®5 dye-labeled free nucleic acids at various 
concentrations was first conducted and linear regression was used to establish a linear fit 
to the linear region of the curve. The label IT® Cy®5 nucleic acid labeling agent was 
purchased from Mirus (Madison, WI). 
2.2.3 Particle Characterization: Size, Charge, and Stability  
The hydrodynamic diameters as well as polydispersity index (PDI) and ζ-potentials 
of the particle were measured by dynamic light scattering (DLS; in 10 mM NaCl 
solution) and laser Doppler anemometry (in 10 mM NaCl solution at pH 7.0), 
respectively, using a Nanosizer ZS90 (Malvern Instruments, Southborough, MA). The 
DNA complexation was confirmed by conventional agarose gel-based electrophoretic 
analysis. Colloidal stability was assessed by monitoring the change in hydrodynamic 
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diameters and PDI in 1x PBS, iso-osmotic NaCl solution (0.9% NaCl), and artificial 
cerebrospinal fluid (aCSF) (Harvard Apparatus, Holliston, MA) at 37 °C. 
 
2.3 Results 
2.3.1 Size and Charge of PBAE mRNA Nanoparticles 
Two types of mRNA were used in this study: EGFP expressing mRNA and 
luciferase expressing mRNA. The optimization of mRNA to TPP ratio was completed 
using luciferase mRNA (Table 1), which showed that a mRNA to TPP mass ratio of 1:2 
provided the lowest positive charge and standard error mean. PEG-PBAE mRNA 
particles carrying EGFP mRNA were also measured for size and charge, which exhibited 
similar trends (Table 2). The addition of TPP was able to decrease the polydispersity 
index and the standard error mean of the 𝛇-potential. The size and charge of un-PEG-
PBAE particles were also included for comparison, along with the PBAE DNA particles. 
The un-PEGylated particles exhibited a relatively larger size of ~100 nm with high 
positive charges above 20 mV. In comparison, the size of both the PEGylated DNA and 
mRNA particles was around 50 nm in diameter and the 𝛇-potential was around 6 mV. 




Table 2: Summary of size and charge for PEGylated and un-PEGylated particles. 
 
 
2.3.2 mRNA Encapsulation and Recovery 
To confirm mRNA compaction in the particles, conventional agarose gel-based 
electrophoretic analysis was performed. The compaction of both EGFP and luciferase 
mRNA were both confirmed for PEG-PBAE mRNA particles with TPP (Figure 1).  
 
Figure 1: Gel electrophoresis confirmation of mRNA compaction in PEGylated 
PBAE particles. The bands represent the following: I) free Luc mRNA, II) free EGFP mRNA, 
III) PEG-PBAE Luc mRNA particles with TPP, and IV) PEG-PBAE EGFP mRNA particles with 
TPP.  
 
I     II    III    IV
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 The concentration of mRNA or DNA plasmids in PBAE particles after washing 
were estimated using RF-5301PC spectrofluorophotometer. A standard curve was 
generated for both mRNA and DNA plasmids using 100% Cy®5 dye-labeled mRNA and 
DNA (data not shown), and the concentration of PBAE particle samples were measured 
after washing. The average recovery rate of genes for PBAE DNA and PBAE mRNA 
particles were 40% and 80%, respectively. This number is later used to calculate the 
appropriate volume needed for a certain dosage when conducting in vitro experiments.  
  
2.3.3 Stability of PBAE mRNA Nanoparticles  
The stability of PEG-PBAE mRNA particles were conducted in three types of 
solutions at 37 C: 1x PBS, iso-osmotic NaCl solution, and artificial cerebrospinal fluid 
(aCSF) to mimic the condition a particle would experience when in the human body and 
brain tissues. The iso-osmotic NaCl solution was derived from our group’s standard 
protocol when conducting brain injections of the nanoparticles, where 1 L of 18% NaCl 
solution is added to 20 L of nanoparticle solution to achieve an iso-osmotic condition of 
0.9% NaCl. The same proportion of 18% NaCl solution and nanoparticles were used to 
test the stability of nanoparticles during the one-hour long injection.  
The stability testings were done on both particles with or without TPP to investigate 
any benefit TPP has in promoting particle stability (Figure 2). The size for both types of 
particles remained stable when incubated in 1x PBS and iso-osmotic NaCl solution, 
fluctuating slightly between 35nm and 70nm over the time period. However, the particles 
with TPP exhibited a significantly better stability than the particles without TPP when 
incubated in aCSF for 5 hours (65 nm versus 465 nm).  
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Figure 2: Stability of PEGylated PBAE mRNA particles in various solutions. A) 
Stability of particles in 1x PBS for a total of 5 hours incubation time, B) Stability of particles in 
iso-osmolar condition using 18% NaCl for one hour of incubation time to mimic injection 
protocol, C) Stability of particles in artificial cerebrospinal fluid for 5 hours of incubation time. 
 
2.4 Discussion 
The established protocol for making PEG-PBAE DNA nanoparticles was able to 
compact mRNA and form particles with sizes similar to the PEG-PBAE DNA NPs, but a 
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more positive 𝛇-potential with high standard error mean was observed, indicating that the 
structural differences between mRNA and DNA such as relative lengths were causing an 
imbalance in surface charge. Upon the addition of anionic tripolyphosphate, the 𝛇-
potential was reduced and was more uniform, which is similar to the characteristics of 
PEG-PBAE DNA NPs. The negative charges on the TPP molecules were probably able 
to interact with and neutralize some of the relatively excess positive charges on PBAE, 
and thus rendering the resulting nanoparticles more neutral. An optimization of TPP to 
mRNA ratio was performed in order to achieve the best possible surface charge, which 
showed that a mRNA to TPP ratio of 1:2 in mass was able to provide a 𝛇-potential of 5 
mV with a reasonable standard error mean. This ratio was used in subsequent in vitro 
experiments for cell uptake and transgene expression testings. Interestingly, the addition 
of TPP was also able to decrease the polydispersity index (PDI) from ~0.25 to 0.14, but 
whether that is due to the neutralization of the excess positive charge on PBAE polymers 
or the cross-linking effect is unknown.  
Another main benefit of TPP addition was observed in the stability of the 
nanoparticles. Although no differences were seen in the nanoparticles stability when 
incubated in 1x PBS and NaCl solution, a substantial improvement in stability was seen 
when the particles were incubated in aCSF. The TPP-added NPs were able to maintain its 
size at around 50 nm, while the size of no-TPP NPs had increased to more than 400 nm in 
diameter. This enhancement in stability could perhaps be explained by the cross-linking 
effect of TPP, allowing the particles to stay intact in the presence of other molecules. 
However, additional experiments would need to be performed to confirm the formation 
of cross-linkages.  
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2.5 Conclusion  
We were able to design a PEG-PBAE mRNA-carrying NPs with a size of 50 nm and 
a 𝛇-potential of 5 mV, which is similar to the previously reported PEG-PBAE DNA-
carrying NPs that showed widespread gene delivery in the brain. The new design includes 
the addition of TPP at a mRNA to TPP mass ratio of 1:2. The addition of TPP was shown 
to reduce surface charge, increase charge uniformity, decrease polydispersity, and 
maintain size stability in artificial cerebrospinal fluid at 37 C.  
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CHAPTER 3: mRNA Nanoparticle In Vitro and Ex Vivo Studies 
3.1 Introduction 
3.1.1 Advantages and Limitations of mRNA Therapy  
Most of the research on gene delivery vectors uses DNA as the cargo of interest, 
despite the several advantages that mRNA has over DNA for gene transfection. The 
advantages include cytosolic delivery, which eliminates the need for nuclear localization, 
and the lack of danger for insertional mutagenesis [29]. However, mRNA also poses four 
main challenges that need to be overcome to achieve good gene transfection: 1) poor 
stability, 2) low translatability, 3) immunogenicity, and 4) inefficient in vivo delivery 
[30]. Several research studies have been done to increase the stability and decrease the 
immunogenicity of mRNA by modifying the sequence with nucleotide analogs such as 2-
thiouridine and 5-methylcytidine. The incorporation of these analogs prevents mRNA 
from engaging with pattern-recognition receptors (PRRs), a group of proteins responsible 
for defending against microbial invasion. Other modifications such as pyrimidine analogs 
were also demonstrated to substantially reduce the expression of cytokines and 
subsequent innate immune reactions [29].  
3.1.2 Current PBAE Nanoparticle System for mRNA 
Due to the advantages of mRNA over DNA and the promising features of PBAE 
polymers, several other groups have also investigated the usage of PBAE polymers to 
delivery mRNA. Su et al. reported a nanoparticle design for vaccination usage that had a 
PBAE core and phospholipid shell with mRNA bounded on the particle surface. They 
reported 30% transfection rate in vitro, but intranasal administration in vivo showed 
inconsistent luciferase expression [31]. Another group reported a PBAE particle design 
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for cancer vaccination usage, which consists of a PBAE polyplex with mRNA and a 
phospholipid shell. The size was around 50 nm, similar to our previous PEG-PBAE DNA 
NP formulation. Their study showed antitumor and anti-metastasis activities when NPs 
carrying ovalbumin (OVA)-expressing mRNA were vaccinated in mice bearing lung 
metastatic B16-OVA melanoma tumors [32]. A third group reported a system for 
reprogramming therapeutic cytoreagents using mRNA nanocarriers. The design includes 
a PBAE core compacted with mRNA surrounded by PGA coating and a layer of targeting 
ligands. When T-cells were transfected for immunotherapy, they achieved 14-day 
survival improvement in B-cell lymphoma mice model [33]. Finally, a group designed a 
nanoparticle consists of PBAE terpolymer copolymer with 7 mol% PEG-lipid coating for 
lung delivery. Intravenous injection of the particles resulted in biodistribution that is 
mostly in the liver but transfection mostly in lungs [34]. None of the above mentioned 
PBAE particles were designed for brain delivery, which further highlights the novelty of 
this research study: formulation of a PEG-PBAE mRNA nanoparticle that provides 
widespread gene delivery in the brain. A table summarizing current PBAE mRNA NP is 















Table 3: Summary of current PBAE nanoparticles design for mRNA delivery   
 
3.1.3 Choice of Glioma Models: GL261 and 9L  
GL261 is a mouse GBM model in C57BL/6 mice that do not require a deficient 
immune system, which allow better comparison to brain tumor growth and immune 
response in human GBM. GL261 shares multiple characteristics with human GBM, 
including its high invasiveness into normal brain, areas of psudopalisading necrosis, key 
mutations such as in the K-ras oncogene and p53 tumor suppressor, and histopathological 
markers such as GFAP, CD31 antigen, VEGF, and HIF-1a [35].    
9L is one of the most widely used glioma tumor models for multiple purposes, 
including radiotherapy, chemotherapy, and imaging. A major distinguishing feature of 9L 
from other glioma models is its sarcomatous appearance under histopathological 
examination, making it similar to gliosarcoma, which is a grade IV brain cancer 
according to World Health Organization [36]. 9L also share some similarities with GBM 
tumor cells such as the biomarker S100, a mutant p53 gene, and EGFR overexpression. 
However, there are also main differences, such as the lack of GFAP expression, PTEN 
tumor suppression gene mutation, and invasiveness [35]. 
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3.2 Materials and Methods 
3.2.1 Formulation of Un-PEGylated PBAE mRNA Particles 
The un-pegulated PBAE mRNA particles were formulated by following a 
protocol described previously [37]. Briefly, mRNA is diluted to 60 μg/mL in 25 mM 
sodium acetate pH 5 buffer (NaAc) and PBAEs were diluted from their stock solutions in 
DMSO in 25 mM NaAc. DNA solution was then added to the PBAE polymers at 
PBAE/DNA mass ratios (w/w) of 60. The resulting mixture was incubated at room 
temperature for 10 min to allow nanoparticles to form. 
3.2.2 Cell Culture 
Two cell lines were used in this study: 9L rat gliosarcoma tumor model and 
GL261 mouse glioblastoma model. 
Highly aggressive mice GL261 glioblastoma cells were provided by Dr. Kannan 
Rangaramanujam. Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
Medium purchased from ThermoFischer Scientific (Waltham, MA) supplemented with 
1% L-Glutamine, 10% heat-inactivated fetal bovine serum (FBS) and 1% 
penicillin/streptomycin from Invitrogen Corp. (Carlsbad, CA). Upon reaching the 
confluent state, the monolayers were treated with trypsin and the dispersed cells were 
transferred into new culture flasks.  
9L rat gliosarcoma model was cultured in Dulbecco's modified Eagle's medium 
(DMEM, Invitrogen Corp., Carlsbad, CA) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Invitrogen Corp.) and 1% penicillin/streptomycin (P/S; Invitrogen 
Corp.). All the following in vitro studies were conducted when cells reached 70% - 80% 
confluency in respective plates. 
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3.2.3 Cellular Uptake of PBAE mRNA Particles 
GL261 Cells were seeded onto 24-well plates at an initial density of 50,000 
cells/well in 500 μL and grown overnight at 37 °C. Cells were treated with different types 
of PBAE nanoparticles: un-PEGylated, PEGylated, and PEGylated plus TPP mRNA or 
DNA particles. The particles carried 60% Cy5-labeled mRNA or DNA plasmids, and 5 
μg of genes were treated in each well. After 5 hours of incubation, the media was 
removed. Cells were then thoroughly washed with 1X phosphate buffered saline (PBS) 
and trypsinized. Flow cytometry was conducted to quantify the cellular uptake of the 
nanoparticles using a Sony Cell Sorter SH800 (Sony, San Jose, CA), followed by data 
analyzed with a FlowJo software (FlowJo LLC, Ashland, OR). 
3.2.4 In Vitro Studies of EGFP Expression in 2D 
The expression of EGFP in a 2D in vitro study was measured using Synergy Mx 
Multi-Mode Microplate Reader (Biotek, Instruments Inc. Winooski, VT). The excitation 
and emission wavelength filters used were 485/20 and 528/20, respectively. The 
background fluorescence from untreated cells were subtracted from the readouts, and the 
resulting differences were analyzed and plotted. 
Confirmation of Microplate Reader Sensitivity 
To ensure the sensitivity of the microplate reader to EGFP fluorescence, in vitro 
dose escalation experiment was conducted. 9L cells were seeded onto black with clear 
flat bottom 96-well plates (Sigma-Aldrich) at an initial density of 5,000 cells/well in 100 
μL and grown overnight at 37 °C. Cells were treated with 0.1 to 1 μg of EGFP mRNA 
using lipofectamine 2000 (Thermo Fisher Scientific, Walthan, MA). After 24 hours of 
incubation, the media was removed to minimize background fluorescence before 
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measuring with the microplate reader to observe any trend of increasing fluorescence 
readings with increasing mRNA dosage.  
Optimal Time Points for Measuring mRNA and DNA Expression 
 9L Cells were seeded onto black with clear flat bottom 96-well plates at an initial 
density of 5,000 cells/well in 100 μL and grown overnight at 37 °C. Cells were treated 
with 0.5 μg of EGFP mRNA or GFP DNA via lipofectamine 2000 (Thermo Fisher 
Scientific, Walthan, MA) and fluorescence was measured at various time points. Cell 
media was removed before each measurement to minimize background fluorescence.  
Comparison of Transgene Expression  
 9L Cells were seeded onto black with clear flat bottom 96-well plates at an initial 
density of 5,000 cells/well in 100 μL and grown overnight at 37 °C. Cells were treated 
with different types of PBAE nanoparticles: un-PEGylated, PEGylated, and PEGylated 
plus TPP mRNA or DNA particles. Lipofectamine 2000 was also included as a positive 
control. Each well was treated with 0.5 μg of EGFP mRNA or GFP DNA, and the culture 
media was replaced with fresh media 5 hours after treatment. The EGFP mRNA and GFP 
DNA expression was measured after 24 hours or 48 hours of incubation, respectively, 
based on previous time point optimization experiments. Cell media was removed before 
each measurement to minimize background fluorescence.  
3.2.5 In Vitro Studies of Luciferase Expression in 2D 
Optimal Time Points for Measuring mRNA and DNA Expression 
GL261 Cells were seeded onto 96-well plates at an initial density of 5,000 
cells/well in 100 μL and grown overnight at 37 °C. Cells were treated with 0.5 μg of 
 29 
Luciferase-expressing mRNA or DNA via lipofectamine 2000 (Thermo Fisher Scientific, 
Walthan, MA) and luciferase assay was conducted at various time points.  
Luciferase Assay 
Cells were seeded onto 96-well plates at an initial density of 5,000 cells/well in 
100 μL and grown overnight at 37 °C. Cells were then treated with either luciferase-
exprerssing mRNA or DNA plasmids delivered by lipofectamine, un-PEGylated PBAE 
mRNA particles, or PEGylated particles at a concentration of 0.5 μg/well. The culture 
media was replaced with fresh media 5 hours after treatment. For transgene expression 
comparison, luciferase assay was conducted after 24 hours or 48 hours of incubation for 
mRNA or DNA, respectively. To do this, media was removed and 100 μl of 1X Reporter 
Lysis Buffer purchased from Promega (Madison, WI) was added. Subsequently, cells 
were subjected to three freeze-and-thaw cycles to achieve complete lysis followed by the 
collection of supernatants by centrifugation. Luciferase activity was measured in relative 
light units (RLU) using a standard Luciferase Assay Kit (Promega) and a 20/20n 
luminometer (Turner Biosystems, Sunnyvale, CA). The RLU values were normalized to 
the total protein content measured by a Bicinchoninic Acid (BCA) Protein Assay Kit 
(Thermo scientific). 
3.2.6 In Vitro Studies of EGFP Expression in 3D Spheroids 
The 3D tumor spheroids were established by the hanging-drop method, which 
cultivates the cells within an agarose matrix created by a house-made spheroid media, 
and then transferred to regular DMEM. The spheroid media was prepared by mixing 
methylcellulose solution at 20% v/v with regular media (DMEM or RPMI). The 
methylcellulose solution was prepared by dissolving autoclaved methylcellulose (Sigma-
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Aldrich) at 2.4% (w/v) in preheated (60 °C), serum-free DMEM followed by dilution 
with an equivolume of DMEM supplemented with 10% FBS and an overnight stirring at 
4 °C. The solution was then centrifuged at 5,000 xg for 2 hours at 4 °C to precipitate 
undissolved methylcellulose and the supernatant was stored at 4 °C until use. To form 
each spheroid, 5,000 cells in 20 μL spheroid media was pipetted onto the lid of a petri-
dish. Spheroids were then grown upside down by covering a PBS-filled/moisturized 
petri-dish with the cell-seeded lid for 2 days. Finally, spheroids were transferred onto a 
sterile U-bottom 96-well plate (CELLSTAR®; Sigma-Aldrich) along with DMEM and 
incubated at 37C for 24 hours prior to their use for subsequent experiments. 
Each spheroid was treated with 1 μg of either EGFP mRNA or GFP DNA 
delivered by lipofectamine, un-PEGylated PBAE mRNA particles, or PEGylated 
particles. The media is replaced with fresh media 5 hours after treatment and the gene 
expression were measured after 24 hours for mRNA and 48 hours for DNA based on 
previous time point optimization experiment. To measure the fluorescence, the spheroids 
were first transferred to a black with clear flat bottom 96-well plates (Sigma-Aldrich) and 
100 μL of trypsin was added to dissemble the spheroids by pipetting multiple times. 
Fluorescence was then detected with the Multi-Mode Microplate Reader (Biotek, 
Instruments Inc. Winooski, VT).  
3.2.7 Cell Viability 
Cells were seeded onto 96-well plates at an initial density of 5,000 cells/well in 
100 μL and grown overnight at 37 °C. Cells were treated with PEG-PBAE mRNA 
particles at a wide range of plasmid doses (0.01 μg to 5 μg per well) for 48 hours at 37 
°C. Cell viability was then assessed using Dojindo cell counting kit-8 (Dojindo Molecular 
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Technologies, Inc., Rockville, MD). Absorbance at 450 nm was measured 
spectrophotometrically using a Synergy Mx Multi-Mode Microplate Reader (Biotek, 
Instruments Inc. Winooski, VT), and cell viability was determined by normalizing the 
readouts to absorbance measured with untreated control cells. 
3.2.8 Ex Vivo Multiple Particle Tracking in Mice Brain 
Multiple particle tracking (MPT) experiments were conducted to quantify the 
diffusion rates of the PEG-PBAE mRNA particle carrying Cy®5-labeled mRNA in 
healthy mice brain parenchyma ex vivo, as previously reported [21, 38]. Briefly, whole 
brain tissues were harvested from 6-to-8-week-old female C57BL/6 mice (Charles River, 
Wilmington, MA) and incubated in aCSF on ice for 10 minutes. The brain tissues were 
then sliced using a Zivic brain matrix slicer (Zivic Instruments, Pittsburgh, PA) and the 
resultant 1.5-mm coronal slices were placed on custom-made slides. Subsequently, 0.5 
μL of PBAE mRNA particles solution at a mRNA concentration of 2 μg/mL was injected 
into the cerebral cortex at a depth of 1 mm using a Neuros syringe (50 μL; Hamilton, 
Reno, NV) mounted on an ultra-precise small-animal stereotactic frame (Stoelting Co., 
Wood Dale, IL). Trajectories of the particles were recorded over 20 seconds at an 
exposure time of 66.7 milliseconds (i.e. 15 frames/s) by an Evolve 512 EMCCD camera 
(Photometrics, Tucson, AZ) mounted on an inverted epifluorescence microscope (Axio 
Observer D1; Carl Zeiss, Hertfordshire, UK) equipped with a 100X/1.46 NA oil-
immersion objective. Movies were then analyzed with a custom-made automated particle 
tracking MATLAB script to extract x, y-coordinates of particle centroids over time from 
which the mean square displacement (MSD) values of individual particles were 
calculated as a function of timescale. Median MSD was determined based on the 
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measured MSD values of individual particles at a timescale of 1 second, at which both 
static and dynamic errors are minimized in MPT experiments [39]. 
3.2.9 Statistical Analysis 
Statistical analysis between two groups was conducted using a two-tailed 
Student's t-test assuming unequal variances. If multiple comparisons were involved, one-
way analysis of variance (ANOVA), followed by Sidak's multiple comparisons test, was 
employed, using GraphPad Software (GraphPad Software Inc., La Jolla, CA). 
Differences were determined to be statistically significant at p < 0.05. 
 
3.3 Results 
3.3.1 Cellular Uptake of PBAE mRNA Particles 
The cellular uptake of PBAE EGFP mRNA particles were measured 5 hours after 
treatment. Both un-PEGylated and PEGylated particles were included in the study as well 
as DNA particles. The Cy®5 intensity represents the relative number of nanoparticles 
internalized by the cell, and the cell uptake percentage represents the amount cells that 
took up detectable amounts of Cy®5 -labeled plasmid payloads.   (~7). Statistical 
significant was detected between the PEGylated mRNA NPs and the PEGylated DNA 
NPs (P <0.0001).   
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Figure 3: Cellular uptake of PBAE nanoparticles. All types of nanoparticles exhibited 
100% cell uptake, but the amount of particle internalized by each cell had significant differences, 
with PEGylated mRNA particles having the highest number and PEGylated DNA particles the 
lowest. (**** denotes a statistical significance of P < 0.0001). 
 
3.3.2 In Vitro Studies in 2D 
Plate Reader Sensitivity Testing 
 A dose escalation study using lipofectamine was conducted to test the sensitivity 
of plate reader to EGFP fluorescence signal and also to create a standardized procedure 
that would ensure consistent and reliable reading outcomes. We saw that when the plate 
was measured with the cell culture media in each well, the slight differences in the 
amount of media per well were able to induce large changes in the fluorescence readings. 
The removal of media before measurement was able to provide more consistent data 
without the influence of background fluorescence (Figure 4). Subsequent experiments 
followed the same procedure when EGFP or GFP signals were measured. 
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Figure 4: Lipofectamine mRNA dose escalation for plate reader sensitivity testing. 
The graph demonstrated that the plate reader is sensitive to EGFP fluorescence when media is 
removed. A clear trend of increasing fluorescence signal can be observed with increasing dosage 
of mRNA treatment.   
 
Time Point Optimization for Luciferase and EGFP 
 Expression of luciferase and EGFP over time were measured for both mRNA and 
DNA to find the time point at which the transgene expression is highest in order to ensure 
valid comparison between mRNA and DNA nanoparticles. The expression of EGFP was 
measured in 9L glioma cells, and the expression of luciferase was measured in GL261 
glioma cells. Two different cell lines were chosen to investigate the ability of the PEG-
PBAE nanoparticles to transfect a variety of cell lines.  
 The highest peak of EGFP mRNA expression appeared 36 hours after treatment 
(Figure 5A), but statistical analysis showed no statistical significance between the 24-
hour and the 36-hour time points, so the 24-hour time point was used for subsequent 
experiments for convenience. The highest peak of GFP DNA expression appeared 60 
hours after treatment, but statistical analysis showed no statistical significance between 
the 48-hour and the 60-hour time points, so the 48-hour time point was used for 
subsequent experiments for convenience. 
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 For luciferase expression, the highest peak for mRNA (Figure 5B) and DNA 
(Figure 5C) occurred 12 hours and 48 hours after treatment, respectively. These are the 
time points used for subsequent experiments.  
 
Figure 5: Transgene expression over time for time point optimization. 
A) EGFP mRNA and GFP DNA transgene expression over 72 hours, B) luciferase mRNA 
transgene expression over 24 hours, C) luciferase DNA transgene expression over 60 hours. 
   
Transgene Expression  
 The transgene expression experiments were conducted with PEG-PBAE particles 
and un-PEGylated PBAE particles to observe the effect of PEGylation. Lipofectamine 
was also used as a positive control. As stated previously, the transgene expression of 
EGFP mRNA delivered via nanoparticles was measured 24 hours after treatment and that 
of GFP DNA was measured 48 hours after treatment in order to compare the highest 
amount of transfection possible for both types of treatment. For luciferase-expressing 
nanoparticles, the transgene expression of mRNA was measured 12 hours after treatment 
and that of DNA was measured 48 hours after treatment. The cell lines used for EGFP-
expressing particles and luciferase-expressing particles were 9L and GL261, respectively.    
 For both EGFP and luciferase particles, the un-PEGylated particles exhibited 
similar transgene expression compared to lipofectamine, and both had significantly 
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higher transgene expression compared to PEGylated particles. When only comparing 
between the PEGylated particles, both types of EGFP mRNA NPs (with and without 
TPP) exhibited higher fluorescence intensity compared to that of the DNA NPs which 
only had a relative fluorescence reading of 135 a.u. (Figure 6A). The PEGylated mRNA 
NPs with TPP also showed slightly higher transgene expression than the particles without 
TPP (751 a.u. versus 714 a.u.), and only the TPP-added NPs demonstrated statistical 
significance when compared to the PEGylated DNA NPs (P< 0.05). For the luciferase 
experiments (Figure 6B), the PEGylated mRNA NPs with TPP showed significantly 
higher luciferase activity than that of both PEGylated mRNA NPs without TPP and 
PEGylated DNA NPs (P <0.05). Different from the EGFP experiments, PEGylated 
mRNA NPs showed slightly lower luciferase activity than the DNA NPs. The figure for 
luciferase activity is plotted on a log scale; the TPP-added NPs exhibited a magnitude of 
108 luciferase activity, while both the regular PEGylated mRNA and DNA NPs exhibited 
a magnitude of 107 luciferase activity. 
 
Figure 6: Transgene Expression in 2D. Transgene expression was investigated with un-
PEGylated and PEGylated PBAE particles. Lipofectamine was included as a positive control. 
EGFP nanoparticles were tested in 9L cell lines, while luciferase nanoparticles were tested in 
GL261 cell lines. The respective subfigures represent the transgene expression for A) EGFP-
expressing nanoparticles and B) luciferase-expressing nanoparticles. (**** denotes a statistical 
significance of P < 0.0001 and * denotes a statistical significance of P < 0.05) 
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3.3.3 In Vitro Studies in 3D Spheroids 
Transgene expression experiment was also conducted in 3D spheroids, which are 
considered to be a better surrogate for screening gene vectors than 2D cell cultures [40]. 
Rat 9L glioma cell line and EGFP mRNA particles were used for this study. 
In general, the transgene expression in spheroids showed similar trends as 
compared to the 2D culture, where the mRNA NPs exhibited much higher fluorescence 
intensity relative to the DNA NPs (Figure 7). However, an important difference is shown 
between the un-PEGylated and PEGylated mRNA with TPP particles, which showed 
similar transgene expression (~900 a.u.), while in 2D culture the un-PEGylated particles 
exhibited much higher transfection compared to the PEGylated particles. The TPP-added 
mRNA NPs showed almost twice as much transfection as the no-TPP PEGylated mRNA 
NPs again showing the benefit of TPP in gene delivery.  
 
Figure 7: Transgene Expression of EGFP in 3D spheroids. The un-PEGylated and 
PEGylated plus TPP mRNA particles showed similar transgene activities and were almost 4 times 
higher than that of the PEGylated DNA particles. The 3D spheroids also more clearly showed the 
benefit of TPP addition in terms of transfection. Efficiency 
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3.3.4 Cytotoxicity of PEGylated PBAE mRNA Particles 
After confirming the ability of our nanoparticle system to induce gene 
transfection in cells, it is also important to evaluate the cytotoxicity of our nanoparticle 
system. Rat 9L glioma cells were treated with a wide range of mRNA dosage, 0.01 to 5 
g, delivered by PEGylated TPP mRNA NPs. The particles showed no signs of 
cytotoxicity after 48 hours of incubation up until a dosage of 2 g, and maintained 80% 
cell viability at 5 g (Figure 8).  
 
 
Figure 8: Cytotoxicity of PEGylated PBAE mRNA Particles with TPP. The particles 
showed no toxicity between 0 and 2 g of mRNA dosage, and was able to maintain an 
80% cell viability at 5 g.   
 
3.3.5 Ex Vivo Tracking 
The diffusion of the PEG-PBAE-TPP mRNA NPs were tested using multiple 
particle tracking ex vivo in mice brain. The median mean square distance (MSD) of the 
nanoparticles is plotted on a log scale with a 1 second time scale (Figure 9A). The 
median MSD of the mRNA NPs is similar to that of the PEGylated DNA NPs, exhibiting 
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similar diffusivity. The trajectory of a particular particle in the brain tissue over a 20-
second period is also plotted and shown (Figure 9B). 
 
Figure 9: Ex Vivo multiple particle tracking. A) The median mean square distance of TPP-
added PEGylated PBAE mRNA particles is compared with the MSD of PEGylated DNA 
particles. B) The trajectory of one particle in the brain tissue over 20 seconds.  
 
3.4 Discussion 
The cellular uptake of different types of particles showed interesting results, which 
indicated that more PEGylated mRNA particles (with and without TPP) were internalized 
compared to un-PEGylated mRNA particles, while the transgene expression was 
significantly higher in un-PEGylated mRNA particles. As several papers have reported 
that while PEGylation helped stabilizing nanoparticles, it also resulted in an reduction in 
endosomal escape and subsequent transgene expression [41, 42], it is not surprising to see 
that a lower cell uptake of un-PEGylated particles could result in higher transfection 
when compared to PEGylated particles.  
The cellular uptake of PEGylated mRNA particles was also significantly higher than 
that of the PEGylated DNA particles. This was surprisingly to see, considering that they 
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have similar sizes and surface charges. One explanation could be that the compaction 
densities of the genes were different, which is possible due to the structural differences 
between mRNA and DNA. Additional experiments would have to be performed to 
confirm this hypothesis.   
The transfection efficiency of the PEG-PBAE mRNA particles was evaluated with 
two types of mRNA (EGFP and luciferase) and in two different types of glioma model to 
confirm the ability of the particle formulation to compact a variety of mRNAs and to 
transfect different cell lines. All of the in vitro testing exhibited similar overall trends, 
where un-PEGylated NPs had the highest transgene expression, followed by PEG-PBAE-
TPP mRNA, PEG-PBAE mRNA without TPP, and finally PEG-PBAE DNA NPs. As 
mentioned above, PEGylation was reported multiple times to cause reduction in 
endosomal escape and therefore transgene expression, and so it is reasonable to see that 
un-PEGylated particles were able to transfect cells more efficiently. The transgene 
expression differences between mRNA and DNA particles could be attributed to two 
factors: 1) DNA particles had lower cellular uptake as shown in the previous cellular 
uptake experiment, and 2) DNA transgene expression requires nuclear localization, while 
mRNA only needs to be delivered to the cytosol. The latter explanation is supported by 
the transgene expression from lipofectamine delivery, which also showed significant 
differences between the transfection efficiency of mRNA and DNA plasmids. 
The transfection efficiency difference between TPP and no-TPP mRNA particles was 
also an interesting observation. A possible explanation for the increase in mRNA 
transgene expression delivered by TPP-added particles is that TPP was able to neutralize 
some of the positive charges on the PBAE polymer and therefore slightly decreases the 
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strong cationic and anionic interactions between PBAE and mRNA, facilitating mRNA 
release and subsequent translation and expression. In addition, the enhanced stability of 
TPP-added mRNA particles could also contribute to the increase in transfection.    
An interesting observation was made when comparing transgene expression between 
2D cultures and 3D spheroids. The transgene expressions of un-PEGylated and 
PEGylated TPP mRNA particles were very similar in 3D spheroids in contrast to the 
difference we saw in 2D cultures. The 3D spheroids were reported to be better 
representation of in vivo environment as they simulate an ECM-filled intercellular 
permeability barrier [43]. The enhanced transgene expression of PEG TPP mRNA 
particles relative to the un-PEGylated particles indicate that the PEG TPP mRNA NPs 
were able to more efficiently diffuse across the ECM-like layer compared to the un-
PEGylated NPs, which would be an important feature for brain penetration.   
Before conducting any in vivo experiments, the cytotoxicity of the particles needs to 
be evaluated. The cytotoxicity of the PEG-PBAE-TPP mRNA NPs were evaluated with 
0.01 g to 5 g of mRNA dosage, which is a significantly high dose of plasmids 
considering the efficacy of current available gene therapies [44, 45]. At 5 g, the cells 
were still able to maintain a high 80% cell viability, showing low signs of cytotoxicity of 
the particles.  
To further validate the penetration and diffusivity of the NPs in brain, an ex vivo 
multiple particles tracking experiment was conducted in mice brain. The mean square 
distance calculated for both mRNA and DNA NPs showed no significant difference, 
which was expected due to the similarity in size and charge. From the trajectories, we 
also saw that the particles exhibit relatively unhindered random motion that spanned 
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several microns over a twenty-second period. This provides a good foundation for us to 
proceed with in vivo experiments in the future to examine the distribution and 
transfection rate across 3D brain tissues. 
 
3.5 Conclusion and Future Directions 
We are able to design a PBAE-based mRNA-carrying nanoparticle system that 
exhibits better transfection efficiency compared to the no-TPP mRNA NPs and PEG-
PBAE DNA NPs (P < 0.05) that were previously shown to achieve widespread gene 
delivery in the brain and improve survival rate. The addition of TPP, which could form 
cross-linkages and mask excess positive charge on PBAE polymers, was able to improve 
the amount of mRNA release and stability of the particles, respectively. Preliminary ex 
vivo experiments also demonstrated promising diffusion in the brain, encouraging us to 
proceed with in vivo testing in the future. 
To further investigate the effectiveness of PEG-PBAE-TPP mRNA NPs in gene 
delivery to the brain tissue, in vivo experiments should be done with fluorescently-labeled 
(Cy®5 ) reporter mRNA such as EGFP or luciferase so that both distribution and 
transfection can be quantified using confocal microscopy. If widespread distribution and 
efficient transfection were observed, gene therapy using mRNA should be tested to 
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